Hyloris Pharmaceuticals SA
EBR:HYL.BR
5.88 (EUR) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Hyloris Pharmaceuticals SA |
Symbool | HYL.BR |
Munteenheid | EUR |
Prijs | 5.88 |
Beurswaarde | 164,642,352 |
Dividendpercentage | 0% |
52-weken bereik | 2.89 - 14.1 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stijn Van Rompay |
Website | https://hyloris.com |
An error occurred while fetching data.
Over Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)